Taking place in New York on May 10, the FT US Healthcare & Life Sciences Summit will review the latest industry trends and their potential implications – from both a patient and price perspective. From gene therapies to the rise in digital treatments, can we afford the age of biology and high tech?
FT US Healthcare & Life Sciences Summit 2018
Bending the Cost Curve: Promise and Prospects
U.S. Food and Drug Administration
With the support of
"This was time well spent. For every discussion I will be researching at least one to more key issues for my own future business needs." David Chianese, GSK
"[The FT US Healthcare & Life Sciences Summit] is unique in that it brings together ALL the various players in the healthcare arena and presents in a format that is both interesting and dynamic." Elizabeth Peck, HSBC
"Spectacular meeting, I plan to attend future FT Summits, I learned more here today than I have learned in professional society meetings, ever about the future of US Healthcare; and I am leaving feeling very confident." Demetrius Maraganore, NorthShore University HealthSystem
Scott Gottlieb was sworn in as the 23rd Commissioner of Food and Drugs on May 10, 2017. Dr Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Advisor to the FDA Commissioner.
He also worked on implementation of the Medicare drug benefit as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency’s coverage process, particularly as it related to new medical technologies.
In 2013 Dr Gottlieb was appointed by the Senate to serve on the Federal Health Information Technology Policy Committee, which advises the Department of Health and Human Services on healthcare information technology.
Dr Gottlieb was previously a Resident Fellow at the American Enterprise Institute, and a Clinical Assistant Professor at the New York University School of Medicine in Manhattan, where he also practiced medicine as a hospitalist physician.
He completed a residency in internal medicine at the Mount Sinai Medical Center in New York, New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.
Elias Zerhouni is the President, Global Research & Development, and a member of the Executive Committee for Sanofi.
Dr Zerhouni’s academic career was spent at the renowned Johns Hopkins University and Hospital where he was Professor of Radiology and Biomedical Engineering and Senior Adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before his appointment as Director of the National Institutes of Health from 2002 to 2008. In that position, he oversaw the NIH’s 27 Institutes and Centers with more than 18,000 employees and a budget of $29.5 billion (2008).
In November 2009, President Obama appointed Dr Zerhouni as one of the first presidential US science envoys.
Dr Zerhouni has founded or co-founded five start-up companies, authored more than 200 publications and holds eight patents and a number of prominent positions on several Boards, including most recently, the board of the Lasker Foundation. He is also a member of the US National Academy of Medicine and U.S. National Academy of Engineering. He received the prestigious Legion of Honor medal from the French National Order in 2008, and was elected in 2010 as a member of the French Academy of Medicine and appointed as Chair of Innovation at the College de France in 2011.
Heather Bresch is the Chief Executive Officer of Mylan. She also serves on the company’s board of directors. As CEO, she is responsible for a workforce of more than 35,000, a powerful global research and development platform, a manufacturing footprint comprising more than 50 facilities and a portfolio of more than 7,500 generic
and branded pharmaceuticals sold in more than 165 countries and territories. Throughout her 25-year career with Mylan, Ms Bresch, who started with the company as a data-entry clerk, has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, she served as Mylan’s President, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan’s Chief Operating Officer and Chief Integration Officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled the size of the company. Ms Bresch emphasizes a collaborative company culture focused on leading, learning, teaching and performing to inspire innovation and help set new standards in healthcare.
Kenneth Abrams is a Managing Director in Deloitte’s Strategy Practice and Deloitte’s Life Science and Health Care National Physician Executive. He is an anesthesiologist with over 30 years of experience as a practicing physician and physician executive in academic medical centers and integrated delivery systems. Dr Abrams has market eminence as a physician leader and as a thought leader in clinical strategy, operations & performance improvement, and clinical integration.
Prior to joining Deloitte, Dr Abrams worked at Northwell Health (formerly North Shore LIJ Health System), where he served as Senior Vice President of Clinical Operations, Chief Quality Officer, and Associate Chief Medical Officer for the health system. He has led multiple projects including a surgical services redesign, anesthesia department turnaround, and the 2010 National Quality Forum (NQF) National Healthcare Quality Award.
Prior to working at the Northwell Health, Dr Abrams was the Patient Safety Officer and Chairman of Anesthesiology at AtlantiCare. His achievements in his five years there included the creation of the Patient Safety Committee, a clinical transformation patient flow project and the creation of a critical care strategic development group, as well as a senior leader in pursuing AtlantiCare’s Baldrige National Quality Recognition. Prior to AtlantiCare, he spent almost 13 years at Mount Sinai Medical Center in New York as Associate Professor of Anesthesiology and Medical Director for Perioperative Services, among other roles.
Dr Abrams holds a Doctor of Medicine (MD) degree from Sackler School of Medicine/Tel Aviv University, an MBA from Zicklin School of Business/Baruch College and a Bachelor’s degree in Biology from the University of Rhode Island.
With 30 years’ experience in pharmaceutical portfolio management, Jenny Alltoft has a proven track record covering all aspects of a product’s lifecycle, including from early R&D to loss of exclusivity. She is a skilled coach and authentic leader, dedicated to unlocking the potential in organizations and team members. In her current role as Global Leader of Pfizer’s Biosimilars business, she leads global strategy, alliance management, M&A, market development and commercialization of biosimilars. Prior to this role, she was General Manager for Pfizer’s Established Products business unit in Australia and New Zealand, managing a portfolio of more than 150 branded and generic medicines used in general practice and hospital settings. Additional career highlights include successfully managing and growing a blockbuster antihypertensive therapy and leading the global team responsible for developing the commercialization strategy for a smoking cessation therapy. Ms Alltoft’s ability to incorporate consumer insights into marketing strategies contributed to a leadership role in establishing Pfizer’s Patient and Marketing Centers of Expertise. In 2004, Ms Alltoft was the recipient of the Healthcare Business
Women’s Association Rising Star Award, reflecting her strengths and achievements in healthcare.
Ashish Atreja has received formal training in public health and is board certified in gastroenterology, clinical informatics and internal medicine. Over the last fifteen years, he has led many public health and informatics initiatives at Cleveland Clinic and Mount Sinai Medical Center, NY that includes developing online education modules, leading EHR implementation, performing analytics on healthcare data and developing enterprise-wide mobile apps. As Chief Technology Innovation and Engagement Officer, Medicine, he leads the Sinai AppLab (www.sinaiapplab.org) that is one of a kind collaborative hub to build and test disruptive mhealth technologies.
Dr Atreja leads scientific registries for American Gastroenterology Association and serves in Innovation Advisory Board for American College of Cardiology. As an intrapreneur, Dr Atreja has won innovation awards at Cleveland Clinic and Mount Sinai, successfully licensed technologies from academic centers and advises startups, accelerators and Fortune 500 companies in digital medicine. More recently, Dr Atreja launched first enterprise-wide app curation and prescribing platform that is licensed to Mount Sinai Spinoff, Responsive Health (http://responsivehealth.org). Recently, Dr Atreja established Network of Digital Medicine (www.nodehealth.org) to connect innovation centers worldwide and share best practices for digital medicine innovation and implementation. Dr Atreja has published more than 60 papers and has presented and advised globally on topics related to digital medicine, patient and health system outcomes.
John Baldoni heads a newly formed drug discovery unit dedicated to explore and apply in silico methodology to drug discovery and development at GlaxoSmithKline GSK). This new appointment follows his role as Senior Vice President, Platform Technology and Science (PTS), GSK Pharma R&D. Dr Baldoni joined GSK in 1989 and has worked in the pharmaceutical industry for 37 years. His experience spans new chemical entity design, development and commercialization, and biopharmaceutical development. In progressing to his current role, Dr Baldoni has held various positions at GSK including Senior Vice President, Preclinical Development; Vice President, Product Development; Director, Product Development; and Assistant Director, Biopharmaceutical Formulation Development, among others. He has led several key cross-functional problem solving and strategic initiatives. Dr Baldoni has a BS in Biochemistry (1974), and MS and a PhD degree in Chemistry (1980) from Penn State University.
Mr Bienaimé is the Chairman and chief executive officer at BioMarin, a fully integrated biopharmaceutical company. He joined the company in May 2005 as Chief Executive Officer and member of the board of directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries.
Previously, Mr Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Prior to Genencor, Mr Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corporation. Mr Bienaimé held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now SanofiAventis), and earlier in his career, he worked at Genentech, Inc. on where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.
Mr Bienaimé currently serves on the boards of Incyte Corporation, a biotechnology company, Vital Therapies, Inc, a biotechnology company and The Biotech Industry Organization. He received an MB from the Wharton School at the University of Pennsylvania and a degree in Economics from the École Supérieure de Commerce de Paris.
William Carson is President & CEO of Otsuka Pharmaceutical Development & Commercialization. He is responsible for leading the team that develops new products and brings them to market, as well as creating strategic plans for the company’s product portfolio to ensure development programs meet quality and safety standards required by medical and regulatory agencies. Since his appointment in 2010, Dr Carson has led the development efforts of compounds in neuroscience, cardio-renal, and oncology. He was instrumental in the development and 2015 FDA approval of REXULTI® (brexpiprazole) for treatment of adults with schizophrenia and as adjunctive therapy in conjunction with an antidepressant medication for treatment of adults with major depressive disorder (MDD). He has also guided the development and registration of Abilify Maintena® (aripiprazole) for extended-release injectable suspension as well as the cardio-renal product SAMSCA® (tolvaptan), marking the first time Otsuka successfully developed and commercialized a product entirely on its own in the United States. He joined Otsuka in 2002 as a board-certified psychiatrist and served the company’s Senior Vice President, Global Clinical Development, overseeing the development of Otsuka-discovered compounds. During his career at Otsuka - and earlier at Bristol-Myers Squibb (BMS) - he was one of the key drivers in the development and commercialization of ABILIFY® (aripiprazole), which Otsuka marketed in collaboration with BMS. Among his many contributions, he led the Aripiprazole Pediatric Efficacy Trials Team, which started the life cycle management programs at Otsuka. Prior to joining Otsuka, Dr Carson was Group Director in Neuroscience Clinical Research and Development at BMS, responsible for the clinical development of ABILIFY. Earlier in his career, he was an Associate Professor and Director of the Inpatient and Partial Hospital Program at the Medical University of South Carolina. Mr Carson received an A.B. degree in History and Science from Harvard University and earned an M.D. degree from Case Western Reserve University.
Steven Corwin is President and Chief Executive Officer of NewYork-Presbyterian, one of the nation’s largest and most comprehensive healthcare delivery networks. Under Dr Corwin’s leadership, NewYork-Presbyterian has nearly doubled in size, providing world-class care to more than 2 million patients per year. Distinguished by its academic partners—Weill Cornell Medicine and Columbia University College of Physicians and Surgeons—NewYork-Presbyterian pursues clinical excellence, engages in pioneering medical research and provides outstanding medical education to the next generation of doctors. For more than a decade, NewYork-Presbyterian is consistently the top-ranked hospital in New York on U.S. News & World Report’s annual survey of “Best Hospitals,” as well as among the top 10 hospitals nationwide.
After having been instrumental in one of the more successful full-asset mergers in the health provider space (NY Hospital and Presbyterian Hospital), one of Dr Corwin’s core focuses as CEO has been on introducing innovative approaches to patient-centered care – with a keen eye on creating new pathways around access to care. Most notably, he led the way in establishing a regional care ecosystem via the NewYork-Presbyterian Regional Hospital Network and NewYork-Presbyterian Medical Groups, which enable patients to receive NewYork-Presbyterian’s world-renowned care directly in their own communities. Dr Corwin also has been a champion for numerous patient-centric technological initiatives, including on-demand access to electronic medical records, telehealth programs and digital health incubation.
Prior to his appointment as CEO, he served as Chief Medical Officer and later Chief Operating Officer. In these roles he led the development and implementation of 13 clinical service lines, a critical step for the success of the newly merged Hospital, and would advance key initiatives around quality and patient safety as well as clinical and technological innovation. Dr Corwin also helped build physician and institutional relationships for the newly merged health system, expand the focus on providing care to underserved communities, and maintain the Hospital’s financial and operational strength. He began his career as a cardiologist and internist at the hospital in 1979.
Dr Corwin serves as President of the Board of Directors of the Greater New York Hospital Association.
Scott Cunning is the Administrative Partner of the Washington, DC office of Haynes and Boone, LLP. Mr Cunning is a patent trial lawyer experienced in a range of technologies, but with a particular focus on helping generic pharmaceutical and biotechnology companies navigate the patent litigation process to bring their products to market. Outside of litigation, he also counsels clients preparing to develop or market generic pharmaceutical or biosimilar drug products.
Mr Cunning’s clients value that over the course of his career, he has invested himself in understanding how the pharmaceutical industry operates so that he can help his clients advance their larger business objectives. Litigation is often a part of the life cycle for commercializing an alternative treatment option, but it is only part of the process. Mindful of the impact that litigation has on a company, Mr Cunning values his role as a counselor as much as a litigator. He develops innovative and effective litigation strategies in close consultation with his clients that minimize disruption and help their businesses succeed.
Ruud Dobber serves as President, US and Executive Vice President, North America of AstraZeneca. In this role, he leads the company’s commercial operations in North America and represents the region as a member of the Senior Executive Team. In these capacities, he is accountable for driving growth and maximizing the contribution of North America to AstraZeneca’s global business. Dr Dobber joined AstraZeneca in 1997 and has held various senior commercial and leadership roles. Most recently, he was Executive Vice President, Europe and oversaw business functions in the 28 EU member states. He was also responsible for the development of our late-stage, small molecule antibiotic pipeline as well as its global commercialization. Prior to that, he was Regional Vice President of AstraZeneca’s European, Middle East and African division, Regional Vice President for the Asia Pacific region and Interim Executive Vice President, Global Product and Portfolio Strategy. Dr Dobber was a member of the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and was earlier Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America (PhRMA). Dr Dobber began his career as a scientist, researching in the field of immunology and aging. He has a Doctorate in Immunology from the University of Leiden in the Netherlands.
Robert Dubois is the Chief Science Officer and Executive Vice President of the National Pharmaceutical Council (NPC). In this role, he oversees the company’s research on policy issues as they relate to the role of real-world evidence in decision making, how to determine the value of health care services, the relationship between access and health outcomes, and the approaches to maintain an environment that supports health innovation. Dr Dubois brings over 25 years of experience in healthcare research, with a key focus on understanding and ensuring that patients receive high value health care. Dr Dubois is also a member of the Medicare Evidence Development and Coverage Advisory Committee, Advisory Board of the Institute for Clinical and Economic Review, the Associate Editor of the Journal of Comparative Effectiveness Research and on the editorial board for Health Affairs and The American Journal of Managed Care. He has published more than 150 peer-reviewed articles.
Dr Jamil El-Imad is a pioneer in virtual reality, artificial intelligence and “big data” for health. A former software engineer, he is currently a research fellow at London’s Imperial College and works on research with other universities (such as the Swiss Federal Institute of Technology, Bonn University, The American University of Beirut and others). Beyond academia and his cutting-edge research, Dr El-Imad is also a serial entrepreneur. He is the Founder and CEO of NeuroPro, which focuses on combining advances in digital technology, signal processing and brain science to achieve practical solutions for the management of neurological and mental health disorders. He is the Chief Scientist, co-founder and co-inventor of Virtually Live media, whose unique patented technology delivers an immersive VR experience for attending live events. He is also the Co-founder and CEO of the Brain Forum which brings together world leaders in science, technology, healthcare and business to advance our understanding of how the brain works and to accelerate the application of that understanding to human needs. Dr El-Imad has an MBA and PhD from the University of Leicester.
Mia Finkelston is a board certified Family Physician with over 20 years of experience in patient care and teaching. She has worked with large Health systems like Penn Medicine and Medstar Health as well as private practice in both the Philadelphia and Southern Maryland regions. Working full time with American Well Corporation, seeing patients online for the last 6 years was never something she thought she would be doing when she graduated from residency, but she has embraced it fully and plans for her colleagues in medicine to do the same.
Oren Frank is a Co-founder and the CEO of Talkspace, the leading online and mobile psychotherapy company that has made therapy accessible and affordable to people across the globe. In a day and age when mental health care is recognized as a global societal crisis, the effectiveness and
convenience Talkspace provides to those seeking to improve their mental health and well-being stands out. Under Oren’s leadership, Talkspace has so far helped more than 500,000 clients connect with licensed therapists — the vast majority of whom had no prior access. As an avid believer in the
power of innovation and technology to better society, Mr Frank founded Talkspace with his wife Roni in 2012, with the vision of “Therapy for all.” After experiencing the benefits of couples therapy earlier in their marriage, they launched Talkspace with the strong belief that mental health care is a moral
right, and everyone should have access to the support and value psychotherapy provides whenever the need or want arises.
Prior to Talkspace, Mr Frank was a successful senior marketing and advertising executive, mostly with McCann Erickson WorldWide, where he was recognized as a progressive creative strategist, and one of the leading voices in the new media-marketing world. Mr Frank maintains that Talkspace helps him redeem and repent for his years spent in advertising.
Tom Frieden is one of the world’s leading public health experts. He is President and Chief Executive Officer of Resolve to Save Lives, a $225 million, 5-year initiative housed at Vital Strategies. Resolve aims to save millions of lives from cardiovascular disease and make the world safer from epidemics. Dr Frieden led control of the largest outbreak of multi-drug resistant tuberculosis to occur in the United States, established the largest effective tuberculosis control program in the world in India, directed efforts that led to a rapid increase in life expectancy in New York City, and oversaw the work of the Centers for Disease Control and Prevention that helped end the Ebola epidemic. A physician trained in internal medicine, infectious diseases, public health, and epidemiology, Dr Frieden has published cutting-edge, widely cited research on a broad range of topics.
Richard Friedman is Professor of Clinical Psychiatry at Weill Cornell Medical College and Director of the Psychopharmacology Clinic in the Department of Psychiatry. Dr Friedman has expertise and research experience in the psychopharmacology and neurobiology of mood disorders, and in particular, treatment-resistant depression. He has done research in the area of depression
At Cornell, he is actively involved in teaching and training psychiatric residents and runs the biological psychiatry curriculum. He is also the Director of the Cornell Student Mental Health Program, which provides psychiatric treatment to medical and graduate students.
Dr Friedman writes for several medical journals, including the New England Journal of Medicine and the Journal of the American Medical Association, on psychiatric topics. He is also a contributing opinion writer at the New York Times where he writes on mental health, addiction, human behavior, and neuroscience.
Robert Grossman, MD, named Saul J. Farber Dean and chief executive officer of NYU Langone Health in July 2007, leads both NYU School of Medicine and NYU Langone Health.
Early in his tenure, Dr. Grossman launched a major campus transformation that will result in the addition of more than 7 million square feet of clinical, education, and research space once complete, including a 365,000-square-foot Science Building and the 830,000-square-foot Kimmel Pavilion, which are slated to open in 2018.
In collaboration with the Board of Trustees and institutional leadership, Dr Grossman has increased NYU Langone’s revenue by nearly $7 billion, and has raised more than $2.4 billion in philanthropy. In addition, NYU Langone’s National Institutes of Health (NIH) 2017 research awards totaled $232 million—an increase of 90 percent since 2007.
Dr Grossman has also curated a new approach to medical education, called Curriculum for the 21st Century (C21). It emphasizes clinical training from the beginning of medical school and includes a revolutionary three-year MD program for select candidates. On U.S. News & World Report’s 2017 Best Graduate Schools list, NYU School of Medicine ranked No. 11 nationally among research-intensive schools of medicine, and No. 2 in New York, out of 140 medical schools nationwide.
Under his leadership, NYU Langone has been ranked by U.S. News & World Report as one of the top 20 hospitals nationwide. In 2016, Modern Healthcare’s Top 100 Hospitals annual survey placed NYU Langone No. 7 among the top 15 major teaching hospitals. A New York City hospital has never made the Top 100 before, and it is the first time in 15 years that a New York State hospital has been represented on the list. For the past four years, NYU Langone has also received top rankings for overall patient safety and quality of care from Vizient, Inc. Additionally, NYU Langone is among just 9 percent of hospitals nationwide to earn a 5-star rating for safety, quality, and patient experience from the Centers for Medicare and Medicaid Services. NYU Langone is the only full-service hospital in the state of New York to earn this distinction.
Dr Grossman is board certified in radiology and neuroradiology, completed his internship at Beth Israel Hospital in Boston (1974), two years of a neurosurgery residency (1974–1976) and a radiology residency (1979) at the University of Pennsylvania, and a two-year fellowship in neuroradiology at Massachusetts General Hospital (1981).
Richard O’Reilly is Chief, Pediatric Bone Marrow Transplant Service; Claire L. Tow Chair in Pediatric Oncology Research. As former Chair of the Department of Pediatrics, Dr O’Reilly oversaw all aspects of the clinical, medical education, and research endeavors the department is privileged to provide. Dr O'Reilly has pioneered transplantation approaches for patients who lack HLA matched siblings. He and his colleagues introduced the use of matched unrelated donors and T-cell depleted transplants from HLA half matched donors in order to provide a normal blood system without graft versus host disease to patients afflicted with lethal immune deficiencies and leukemia. He also introduced the use of immune cells for the treatment of virus-induced lymphomas. He is also an authority on transplantation immunology and cellular therapies.
Dr O’Reilly is past-President and currently a member of the Board of the Damon Runyon-Walter Winchell Cancer Fund, and on the Board of the Children’s Oncology Society of New York, which runs the local Ronald McDonald House. He has won several awards for his work, including honors from the American Society of Clinical Oncology, the Society of Translational Oncology, the American Society for Blood and Marrow Transplantation, and Leiden University in The Netherlands. Dr O’Reilly has an MD from the University of Rochester School of Medicine.
Larry La Motte
The Honorable Larry La Motte created Advocacy Options after nearly 10 years working as Vice President of Public Policy for the Immune Deficiency Foundation (IDF) and a successful career in business and as an elected official in the General Assembly of the State of Maryland. Advocacy Options provides patient-centric services in the area of advocacy for patient advocacy organizations and providers.
During his almost ten-year tenure with IDF, Mr La Motte built a public policy unit and greatly enhanced IDF’s public policy profile across the country. Among other things, his efforts focused on eliminating barriers to care faced by many people with rare and chronic diseases from publicly funded payers such as Medicare, Medicaid, Marketplace plans and commercial payers. He also led two national coalitions, Patients for Biologics Safety and Access (PBSA) and the American Plasma Users Coalition (APLUS). Both coalitions were dealt with issues related to patient safety and access to care. PBSA was very active in raising the voices of patients regarding the policies being set by the FDA’s pathway for Biosimilars. And APLUS has played a large role regarding blood safety issues at the FDA.
Mr La Motte’s interest in health policy issues crystallized while serving 12 years as an elected official in the House of Delegates in Maryland. In that capacity, he served on the Environmental Matters Committee as Chairman of the Subcommittee on Health and Environment. Virtually all health and environmental legislation came before his subcommittee. He continues to be active in the Baltimore community having served on the boards of a hospital, a non-profit health services provider and now a committee of the Maryland Hospital Association.
Steven Pearson is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent non-profit organization that evaluates the evidence on the value of medical tests, treatments, and delivery system innovations to encourage collaborative efforts to improve patient care and control costs. Prominent among its evidence reports are ICER reviews of new drugs that include full assessments of clinical and cost-effectiveness along with suggested “value-based price benchmarks” to inform policymakers and guide price and coverage negotiation. Dr. Pearson is a Lecturer in the Department of Population Medicine at Harvard Medical School and also serves as Visiting Scientist in the Department of Bioethics at the National Institutes of Health.
Eric Perakslis is currently Chief Science Officer at Datavant, an innovative new company with the mission to organize the worlds healthcare data. He is also Visiting Scientist in the Department of Biomedical Informatics at Harvard Medical School (HMS) and a frequent volunteer advisor to Médecins Sans Frontières and other international aid and relief NGOs. Most recently, Dr Perakslis was Senior Vice President and Head of the Takeda R&D Data Science Institute where he built an integrated institute of more than 165 multi-disciplinary data scientists serving all aspects of biopharmaceutical R&D and digital health. Prior to Takeda, he was the Executive Director of the Center for Biomedical Informatics and the Countway Library of Medicine, an Instructor in Pediatrics at Harvard Medical School and a faculty member of the Children’s Hospital Informatics Program at Boston Children’ Hospital. While at HMS, Dr Perakslis focused on the approval of the Department of Biomedical Informatics as a full academic department at HMS, the development of the NIH Undiagnosed Diseases Network, industry collaborations, leading the technology efforts for multiple Ebola response programs, and building active research programs in medical product development, regulatory science and cyber security. Prior to HMS, Dr Perakslis was the Chief Information Officer and Chief Scientist (Informatics) at the U.S. Food and Drug Administration. In this role, Eric authored the first IT Strategic Plan for FDA and was responsible for modernizing and enhancing the IT capabilities as well as the in silico scientific capabilities at FDA. Before serving at the FDA, Dr Perakslis was Senior Vice President of R&D Information Technology at Johnson& Johnson Pharmaceuticals R&D and member of the Corporate Office of Science and Technology. During his thirteen years at J&J, he also held the posts of Vice President R&D Informatics, Vice President and Chief Information Officer, Director of Research Information Technology and Director of Drug Discovery Research. Prior to J&J, he was the Group leader of Scientific Computing at ArQule Inc. Dr Perakslis gained his PhD in Chemical and Biochemical Engineering from Drexel University and also holds B.S.ChE and M.S. degrees in Chemical Engineering.
Julia Pike is Vice President of IP, North America at Sandoz. In this position, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the recent landmark US Supreme Court decision, Sandoz v Amgen. Since leaving private practice at Corrs Chambers Westgarth, Ms Pike has been in-house counsel for many years including at Mayne Pharma and Hospira Inc. She joined Sandoz in 2008, at which time she had responsibility for Sandoz’s European public affairs, including development of the Unified Patent Court and the European environment for biosimilars. From 2010 to 2015, she led Sandoz’s global IP litigation function as Global Head of IP Litigation. In her IP focussed roles, she was responsible for IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world. She has maintained an active role and interest in shaping the IP environment worldwide. Ms Pike is a regular participant and speaker at life sciences and IP conferences, and an author of the European Generic Medicines Association report, “Patent-Related Barriers To Market Entry For Generic Medicines In The European Union”. Ms Pike earned her Master of Laws (Intellectual Property) from the University of Melbourne, and also holds a Bachelor of Laws/Bachelor of Science degree.
Andrew Radin is Co-founder and Chief Executive Officer of twoXAR, an artificial intelligence-driven drug discovery company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry and investor partnerships. Mr Radin developed the company's proprietary algorithm and leads product development. Prior to co-founding twoXAR, He held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world. Mr Radin studied biomedical informatics in Stanford University's SCPD graduate program and holds Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.
George Savage is Chief Medical Officer and Co-Founder of Proteus Digital Health, and formerly the company’s Vice President of Research and Development. He is a member of the team of leaders from both Otsuka and Proteus that created and secured FDA approval for Abilify MyCite, the world’s first Digital Medicine manufactured with an integrated ingestible sensor. He sees Digital Medicine as an invaluable collaboration platform for patient and physician, integrating information about a patient’s response to therapy directly into everyday healthcare.
Dr Savage serves on the board of the California Life Sciences Association, the Boston University College of Engineering Advisory Council, and in 2016 was elected a Fellow of the American Institute for Medical and Biological Engineering.
Christi Shaw re-joined Eli Lilly and Company in April 2017 as Senior Vice President and President of Lilly Bio-Medicines. Leading Lilly’s broadest therapeutic portfolio, she oversees late-stage clinical development and commercialization for the company’s leading positions in Immunology, Pain and Alzheimer’s disease, some of Lilly’s most significant opportunities to make life better for patients. She also leads commercial responsibilities in the world’s largest markets for Lilly medicines in neuroscience, men’s health and osteoporosis.
After beginning her career at Lilly in 1989, Ms Shaw has held positions of increasing influence and authority across the bio-pharmaceutical industry over three decades, including leadership positions at Lilly, Johnson & Johnson and Novartis, where she most recently served as US Country Head, President of Novartis Corporation and President of Novartis Pharmaceuticals Corporation. Her leadership spans a broad range of therapeutic areas, including oncology, cardiovascular and respiratory, dermatology, immunology, neuroscience, ophthalmology and medical devices.
Ms Shaw has served on the boards of the Biotechnology Industry Organization (BIO), the Healthcare Leadership Council and the Young Women’s Leadership Network. In May 2016, she was presented with Eye for Pharma’s prestigious “Lifetime Achievement Award” for her industry thought-leadership and dedication to the needs of patients. PharmaVOICE also named Ms Shaw to its “100 Most Inspiring People” list in 2016, and Diversity Journal included her in its list of “Women Worth Watching.” Ms Shaw has spoken at leading industry conferences on the future of healthcare, driving innovation to support better patient outcomes and encouraging a diverse and inclusive culture. In addition, her perspectives have been featured in Working Mother and Life Science Leader.
In 2017, Ms Shaw founded the More Moments More Memories Foundation to assist people with cancer and their caregiver. A proud native of Iowa, Shaw and her sisters own and manage a number of local farms, advancing innovative green methods to promote sustainability, conservation and forest preservation, while supporting future independent farmers. She earned an MBA from the University of Wisconsin and a BBA from Iowa State University.
Christine Simmon is the Senior Vice President of Policy & Strategic Alliances and Executive Director of the Biosimilars Council of the Association for Accessible Medicines (AAM), founded in 2015. In this role, she is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council and building relationships with strategic partners in the health care sector, including patient advocacy groups.
Previously, she served as Vice President of Policy, Public Affairs & Development at AAM from 2002 to 2006. Before rejoining the association, she was the Senior Director of Public Policy for CVS Caremark, where she was the policy lead for the integrated retail, convenient care clinic and PBM enterprise at both the state and federal levels. Prior to that, she was a Senior Policy Analyst at BlueCross
Ms Simmon received her JD from Georgetown University Law Center and her BA in American Studies from Georgetown University.
Andrea Heslin Smiley
Andrea Heslin Smiley serves as President and Chief Executive Officer of VMS BioMarketing, a patient support solutions company utilizing nurse educators to improve patient adherence and outcomes. Ms Smiley serves on numerous boards including the Egalet Corporation and several prominent charitable organizations. She joined VMS BioMarketing in July 2008 to lead the company’s strategic marketing and brand development business groups and was named President and CEO in 2011. Prior to VMS, Ms Smiley was an executive at Eli Lilly and Company where she worked for 12 years in strategic business development roles as well as increasingly senior leadership positions in the diabetes, growth hormone, and osteoporosis business units. She has launched multiple biotech and pharmaceutical drugs and devices in injection-naïve markets, negotiated product labels with the FDA, led the development of Eli Lilly and Company’s first Risk Management Plan, repositioned late-stage products that resulted in increased market share growth, and developed and implemented customer-focused sales models. She began her career with Harvard University as a business development analyst and was a management consultant with Putnam Associates, a Boston-area firm focused on companies in the pharmaceutical, biotechnology, and diagnostics businesses. Ms Smiley received a gubernatorial appointment to the Indiana Commission for Women. She earned her BA in economics from DePauw University where she was an Honors Management Fellow, and is a graduate of the Harvard Business School executive education program.
Tom Stanis is Head of Engineering at Verily Life Sciences. He heads projects including the development of machine learning algorithms for applications ranging from robotic-assisted surgery to diabetes management. Prior to joining Verily, Mr Stanis spent nine years working on core Google products and five years at Electronic Arts (EA). Throughout his career, his focus has been on improving the user experience, performance and scalability of systems through cross-functional collaboration. Mr Stanis received his B.S. from UW Madison.
Mark Trusheim is Strategic Director, NEWDIGS, at MIT where he also co-leads the Financing and reimbursement of Cures in the US (FoCUS) Project. He is also a Visiting Scientist at the MIT Sloan School of Management. In addition, through MIT, he has served as a Special Government Employee for the FDA’s Office of the Commissioner. Mr Trusheim’s research focuses on the economics of biomedical innovation, especially precision medicine, adaptive pathways, platform trials and digital health advances. Prior to MIT, his career spanned big data at Kenan Systems, marketing at Searle Pharmaceuticals, eHealth as Vice President of Monsanto Health Solutions, genomics as President of Cereon Genomics and policy as the President of the Massachusetts Biotechnology Council. Mr Trusheim holds degrees in Chemistry from Stanford University and Management from MIT.
Stephen Ubl is President and Chief Executive Officer of Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America's leading biopharmaceutical research companies. Mr Ubl leads PhRMA's work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery, and access to life-saving medicines. "If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr Ubl," the New York Times' Robert Pear wrote in February 2016. "He is more conversant with the intricacies of health policy, and more adept at the politics." He is routinely recognized as one of Washington’s most effective advocates, and, in 2017, was named for the second year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare.” In 2016, he was named a Top Lobbyist by The Hill and a top health influencer by Medical Marketing & Media and PR Week magazines.
Martha Whitecotton is responsible for strategic development, execution and oversight for the Behavioral Health Service Line for Atrium Health across all care settings as well as physician services. She works in a dyad leadership model with the Chief Clinical Officer to build and manage a clinically relevant and fiscally prudent organization that will help meet the current and future mental health needs of the community in the growing Atrium Health coverage area. With a specific focus on integrating behavioral health into primary care, this team is creating a forward-thinking, innovative, value-based care delivery model for ambulatory care, driving screening and treatment upstream, leveraging a virtual care platform.
Prior to assuming this role, Ms Whitecotton served as the President of Levine Children’s Hospital with responsibility for hospital operations, emergency services, and ambulatory specialty care. Ms Whitecotton led the strategic development of key programmatic elements at the Children’s Hospital including the Congenital Heart Center, Pediatric Inpatient Rehabilitation and a Blood and Marrow Transplant program; leading the hospital to national rankings in cardiac care, cancer, oncology, nephrology, orthopedics and neonatology within five years of the opening.
Gail Wilensky is an Economist and Senior Fellow at Project HOPE, an international health foundation. Her expertise is on strategies to reform healthcare, with particular emphasis on Medicare, comparative effectiveness research and military health care. She testifies frequently before Congressional committees, serves as an adviser to members of Congress and other elected officials, and speaks nationally and internationally. She is also a director on Quest Diagnostics and United Health Group boards. Dr Wilensky also currently serves as a trustee of the Combined Benefits Fund of the United Mine Workers of America and the National Opinion Research Center, is on the Board of Regents of the Uniformed Services University of the Health Sciences (USUHS) and the Board of Directors of the Geisinger Health System Foundation. She is an elected member of the Institute of Medicine and has served two terms on its governing council. She is a former chair of the board of directors of Academy Health, a former trustee of the American Heart Association and a current or former director of numerous other non‐profit organizations. Previously, she directed the Medicare and Medicaid programs and served in the White House as a senior adviser on health and welfare issues to President GHW Bush. She was also the first chair of the Medicare Payment Advisory Commission She received a Bachelor’s degree in Psychology and a PhD in economics at the University of Michigan and has received several honorary degrees.
Kurt Wrobel is the Chief Financial Officer and Chief Actuary of Geisinger Health Plan, and a Fellow of the Society of Actuaries. He serves as the Chief Actuary of Geisinger Indemnity Insurance Company and Geisinger Quality Options, Incorporated. Mr Wrobel joined Geisinger Health Plan in 2014. Prior to this, he was a consultant for Milliman in Brookfield, Wisconsin. He also served as Vice President of large-group pricing and underwriting and as Chief Underwriting Officer for Humana, based in Louisville, Kentucky. He also held positions at United Healthcare/PacifiCare Health Systems, based in California, at HealthMarket, Inc, based in Texas and at William M. Mercer Inc, in Milwaukee, Wisconsin. In addition, he has published several actuarial articles on healthcare reform, risk management and payment reform initiatives. Mr Wrobel earned a BA degree in Economics from the University of California, Los Angeles. He also has an MSc degree in Economics from the University of Wisconsin, Madison, and an MBA in Healthcare Management from The Wharton School, University of Pennsylvania, in Philadelphia.
Chairs and Moderators (3)
David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.
Mr Crow has an MA in English Literature from the University of Glasgow.
Sarah Neville is Global Pharmaceuticals Editor of the Financial Times, a position she has held since 2016. She joined the Financial Times in 2001 and has held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and Public Policy Editor. She began her career on local and regional newspapers, eventually becoming Political Editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post.
Mike DeLone is the leader of Deloitte’s US Consulting Life Sciences practice. He has over 20 years of experience dedicated to the life sciences industry and is responsible for prioritizing the signature issues, products, solutions, services and delivery models the practice takes to market across our advantaged client portfolio in Bio-Pharma, MedTech, Generics and Consumer Health businesses. Prior to his role in leading the US Life Sciences Consulting practice, he lead Deloitte’s Life Sciences Consulting Technology practice in the US, focusing across all areas of information technology, digital and analytic transformations. Mr DeLone specializes in information management and analytics solutions, strategies and organization.
Mr DeLone has led business and technology transformations at clients such as Pfizer, Novartis, Biogen, Merck, Boston Scientific, Johnson & Johnson, Philips Healthcare and EMD Serono, as well as other notable companies including BMW, Dun & Bradstreet, Philip Morris and Fannie Mae. His work with these organizations has included the definition, requirements, design, implementation and support of large scale transformations. He has also spent significant time helping these organizations with the definition and improvement of technology strategy and related organizational and business alignment.
Mr DeLone is a thought leader in information management and business intelligence, specifically applied to the life sciences industry. His client work has been presented as examples of leading practices at The Data Warehousing Institute, CFO World, Hyperion, IBM World, and other conferences. He has been a guest speaker for the Villanova University MBA Program in the area of business technology strategy. Mr DeLone is a board member and recent board chair of BreastCancer.Org.
The world is sitting on the cusp of a new era in medicine. In the coming decade, the life science industry is poised to bring forward a whole range of cell, gene and other advanced therapies that hold the promise of cures for serious conditions for which there is no effective treatment. Advances in AI, cognitive robotics, blockchain and health IoT, meanwhile, offer huge potential to transform the industry. From early diagnosis and prevention to virtual nursing assistants, and the transformation of R&D, no area of the business will remain untouched. Yet the high price tag commanded by advanced treatments means that radically new ways will need to be found to enable patient access and ensure the sustainability of the healthcare system. And there are many challenges to be addressed before the full potential of the digital transformation can be realized. Can we afford the age of biology and high tech? How will the future unfold?
The FT US Healthcare and Life Sciences Summit, now its seventh successful year, will bring together industry leaders from across the healthcare and life sciences continuum to explore the major transformations ahead.
Agenda - 10th May
Realizing the Potential of Digital Health: Insight on the Development and Approval of the first Digital Medicine Product
Data analytics and behavioral tools are causing a seismic shift in the way medicine is practiced worldwide. The November 2017 approval of ABILIFY MYCITE®, the first digital medicine to be approved by the US FDA, marked a major step forward in the digital health revolution. Dr Carson will reflect on the process and collaboration between the pharmaceutical industry and Silicon Valley to bring the vision of digital medicine to life. He will examine the collaborative approach, advanced regulatory pathways and look ahead to the impact this first digital medicine approval may have on the future of healthcare and the opportunity of increased data and analytics.
William Carson, President & CEO, Otsuka Pharmaceutical Development & Commercialization and George Savage, Co-founder, Chief Medical Officer, Proteus Digital Health in conversation with Sarah Neville, Global Pharmaceuticals Editor, Financial Times
9:00amOpening Remarks from the Chair
David Crow, Senior US Business Correspondent, Financial Times
9:05amKeynote Opening Address
Elias Zerhouni, President, Global Research & Development, Sanofi
9:20amTaking the Pulse: The Future of US Healthcare Reform
With the availability and affordability of healthcare an overriding concern for a majority of Americans, the issue of healthcare reform will continue to play a central role on political agendas.
- What has been the legacy of reforms to date, and what proposals are now on the table to bend the curve on healthcare costs?
- What does the end of the individual mandate mean for the health exchanges?
- What would be the impact of efforts to introduce market-style reforms to Medicaid and Medicare?
- What do the proposed mega-mergers between CVS, Aetna, Cigna and Express Scripts mean for US healthcare?
- How will reform of the 340B drug discount program affect healthcare costs?
Steve Corwin, President and CEO, NewYork-Presbyterian
Ruud Dobber, President, US and Executive Vice President, North America, AstraZeneca
Gail Wilensky, Economist and Senior Fellow, Project HOPE
Kurt Wrobel, Chief Financial Officer and Chief Actuary, Geisinger Health Plan; Fellow, Society of Actuaries
Moderator: David Crow, Senior US Business Correspondent, Financial Times
10:05amCan We Afford the Age of Biology? Preparing Health Systems for the Next Wave
We are on the cusp of a new era in medicine. The industry is poised to bring forward a whole range of new gene, cell and other similar advanced therapies that hold the promise of treatment and cures for a diverse range of serious and costly conditions for which there is currently no effective treatment. However, the six-figure price tag likely commanded by these products, as well as the number of patients potentially impacted (some 10% of the US population have a gene linked to a hereditary disease, for instance) raises the issue of affordability for patients, and for already squeezed public and private payers. New ways will need to be found to monetize the benefits of these new therapies, enable patient access and ensure the sustainability of healthcare systems.
- With the advent of this new frontier in innovation, will we see costs continue to rise inexorably, with no end in sight, or will innovation across the system ultimately succeed in maintaining a lid in costs?
- Do we risk creating a chasm between those who can afford the era of personalized medicine and those who cannot?
- What are the viable alternative pricing and financing models to ensure the full potential of these new treatments are realized and their affordability and access is assured?
- How do you value potential cures?
Jean-Jacques Bienamé, Chairman and Chief Executive Officer, BioMarin
Robert Dubois, Chief Science Officer and Executive Vice President, National Pharmaceutical Council (NPC)
Steven Pearson, Founder and President, Institute for Clinical and Economic Review (ICER)
Mark Trusheim, Strategic Director NEWDIGS, MIT Center for Biomedical Innovation; Visiting Scientist, MIT Sloan School of Management
Moderator: David Crow, Senior US Business Correspondent, Financial Times
10:50amNetworking Coffee Break
Thomas Frieden, President and CEO, Resolve to Save Lives
11:25amDoing the Patent Dance in the Biosimilars Era
The passing of bipartisan generic drugs legislation in the 1980s, which was designed to speed up the introduction of cheaper medicines, is held up by the pharmaceuticals industry as a grand compromise that found a balance between affordability and protecting intellectual property. Today, roughly 9 out of 10 US prescriptions are filled with "copycat' drugs that are a fraction of the price of the branded original, giving the cash-strapped healthcare system headroom to afford new prescription medicines. But today's best-seller lists are dominated by biological drugs that cannot be directly copied. Will nearly-the-same or "biosimilar" versions have the same deflationary effect?
- Are biosimilars "therapeutic equivalents" that should be prescribed in place of branded drugs, or should they be treated as new entrants that have to prove their worth to patients and doctors?
- Will biosimilars follow generics in exerting the same downward pressure on drug prices? If not, how can healthcare systems afford to pay for new medicines?
- And what of the future of the Patent Office's quasi-judicial process for invalidating intellectual property? Will the Supreme Court agree with petitioners who say it extinguishes private property rights when it rules on the matter in June 2018
- If the Patent Office procedure does survive, will we see more attempts to skirt its authority, such as transferring patients to entities with sovereign immunity like universities and Native American tribes?
Jenny Alltoft, Global Biosimilars Lead, Pfizer Essential Health
Scott Cunning, Partner, Intellectual Property Litigation Practice, Haynes and Boone
Larry La Motte, Principal Consultant, Advocacy Options
Julia Pike, Vice President of IP, North America, Sandoz
Christine Simmon, Senior Vice President of Policy & Strategic Alliances; Executive Director, The Biosimilars Council, Association for Accessible Medicines (AAM)
Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times
Heather Bresch, Chief Executive Officer, Mylan in conversation with David Crow
FT Keynote Interview:
Stephen Ubl, President and Chief Executive Officer, Pharmaceutical Research and Manufacturers of America (PhRMA) in conversation with David Crow.
What are the implications of healthcare reform in the real world, where it matters most - at the interface with the patient in the clinic, or increasingly perhaps on screen with a digital doctor? Physicians have a unique, frontline perspective on healthcare reform and the transformation of the healthcare system: they remain a key gatekeeper and influencer in the relationship with the patient and in the on-going efforts to manage costs through payment reforms such as is as MACRA.
In this session, leading physicians will share their perspective on the new ideas and concepts that will transform healthcare in the coming years-the scientific and technological breakthroughs and the fast changing financial and business models. What do healthcare reforms mean to them and how do they see the way forward? How are they keeping up with AI, gene therapies, the era of personalized medicine and all manner of innovation set to ‘transform for the future of clinic care’? Are physicians being adequately schooled for the next generation of medicine? Will their profession be upended by the dawn of AI, robotics and the new age digital doctor?
Kenneth Abrams, Managing Director, Physician Executive, Deloitte
Mia Finkelston, Medical Director, Online Care Group (OCG), American Well
Robert Grossman, Dean and Chief Executive Officer, NYU Langone Health
Richard O’Reilly, Chief, Pediatric Marrow Transplant Service; Claire L. Tow Chair in Pediatric Oncology Research, Memorial Sloan Kettering Cancer Center
Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times
Andrea Heslin Smiley, President and CEO, VMS BioMarketing in conversation with Sarah Neville
2:45pmThe Opioid Crisis and Beyond: The Future of Mental and Behavioral Health
The on-going opioid crisis in the US, with its many behavioral determinants, has brought into sharp focus the state of mental health services and the need for new approaches to close critical gaps in diagnosis, treatment and care. With some 30% of the population expected to experience mental illness in their lifetime and the numbers of elderly patients with neurological diseases set to grow, the potential to lower costs to the healthcare system whilst boosting health outcomes linked to motivation and adherence is significant.
- How could mental health be done differently? How can continuing stigma be tackled?
- What are the emerging models and solution e.g. greater integration of physical and mental health and social services, the role of social entrepreneurs such as ‘outreach well-being services’?
- What are the challenges and implications of a new era of digital psychiatry and therapies? How is validation, regulatory, reimbursement and other challenges being addressed? Are digital therapies as effective as in-person treatment? What is the cost-saving potential for healthcare systems?
Session Keynote: Christi Shaw, President, Lilly Bio-Medicines
Jamil El-Imad, Honorary Senior Research Fellow, Department of Electrical and Electronic Engineering, Imperial College, London; Founder and CEO, NeuroPro; Co-Founder and CEO, Brain Trust
Oren Frank, Co-founder and CEO, Talkspace
Richard Friedman, Professor of Clinical Psychiatry; Director of Psychopharmacology Clinic, Department of Psychiatry, Weill Cornell Medical College
Martha Whitecotton, Senior Vice President, Behavioural Health Services, Atrium Health
Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times
Scott Gottlieb, Commissioner, U.S. Food and Drug Administration (FDA)
3:50pmAI, Robotics, Blockchain and the Digital Transformation of Healthcare and Life Sciences
Exponential technologies to include AI, cognitive robotics, blockchain health IoT, have the potential individually and cumulatively to transform the business of healthcare and life sciences. From early diagnosis and prevention, to virtual nursing assistants, robotic-assisted surgery, fraud detection, risk and workflow management, no area of clinical and operational business of health will remain untouched. And the potential impact on the life science industry more specifically is equally immense-transforming clinical trial management, lead generation and the current ‘‘inherently inefficient and costly drug development process’? However, the jury is still out-will these advanced technologies remove costs or ultimately add to costs of the healthcare system?
- How will AI improve human health?
- What are the potential applications, their value and their ability to cut healthcare costs?
- What are the workforce implications? Will these new technologies supplant, complement or augment current healthcare jobs?
- What are the regulatory challenges?
Session Keynote: Ashish Atreja, Chief Innovation and Engagement Officer, Medicine, Icahn School of Medicine at Mount Sinai
John Baldoni, Senior Vice President, DPU Head, In Silico Discovery, GlaxoSmithKline
Eric Perakslis, Chief Science Officer, Datavant
Andrew Radin, Co-founder and CEO, twoXAR
Tom Stanis, Head of Engineering, Verily Life Sciences
Moderator: Mike DeLone, US Life Sciences Consulting Leader, Deloitte
David Crow, Senior US Business Correspondent, Financial Times
- Take the pulse of healthcare reform: what’s really happening on the Hill?
- Discuss the repercussions of the ‘age of biology’ and the promise of cures for healthcare access and affordability
- Hear how AI, cognitive robotics and blockchain will transform the business of health
- Gain insights into the future of mental and behavioral health: can digital therapies replace in -person treatment?
- Get real life perspectives on the unfolding transformation of health-from the physicians at the front line of patient care and clinical transformation
- Hospital, Health Systems, Accountable Care Organisations (ACOS) and Physician Networks
- Government Payers and Private Health Insurers
- Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies, Pharmacies
- Medical Devices and Diagnostics
- Digital Health and Healthcare IT (Patient records, data, mobile healthcare applications, social media)
- Investment (Fund Managers, Venture Capitalists, Private Equity firms, Investment Bankers, IP Groups, Health Insurance, Investment Banks)
- Legal Counsel and Consultants
- Regulators and Government Agencies
Presented by (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. In 2016 the FT passed a significant milestone in its digital transformation as digital and services revenues overtook print revenues for the first time. The FT has a combined paid print and digital circulation of more than 910,000 and makes 60% of revenues from its journalism.
With the support of (1)
About Life Sciences and Health Care at Deloitte*
Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.
Lead Sponsors (2)
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Breakfast Sponsor (1)
Otsuka Pharmaceutical Company is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These companies’ 1,800 employees in the U.S. develop and commercialize medicines in mental health, oncology, cardio-renal and nephrology, using cutting-edge technology to address unmet healthcare needs. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately USD 11 billion in 2016.
Luncheon Sponsor (1)
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone.
VMS BioMarketing is a leading provider of patient support solutions focused on empowering patients and healthcare providers through education, training, and ongoing health coaching. For more than 20 years, VMS has been dedicated to enabling Clinical Educators to provide the personalized support necessary to help patients successfully start and stay on therapy. VMS clients include the world’s leading pharmaceutical and biotechnology companies.
Supporting Partners (4)
The essential briefing for decision makers in health
FT Health is a weekly guide to the news and analysis that matters for decision makers in government, healthcare, research, industry and policy-making around the world. Leading specialists curate the best articles from the FT and across the web and make the links between the big issues. FT Health signposts important coverage on topics including infectious and non-communicable disease, public health, healthcare policy and practice, public health, research, development, drugs, vaccines and diagnostics. Straight to your inbox every Friday.
When members of the Healthcare Businesswomen’s Association (HBA) come together, it’s with a shared purpose: to be a united force for change. We connect diverse groups of both women and men, across all healthcare and life science disciplines. By taking focused action to advance our mission, we are creating a powerful movement that directly drives professional opportunity and corporate growth. We believe that by joining forces in the relentless pursuit of gender parity, we are doing more than uniting individuals—we are strengthening the business of healthcare.
In 2011, StartUp Health introduced a new model for transforming health by organizing, supporting, and investing in a global army of entrepreneurs called Health Transformers. With the world’s largest digital health portfolio (230+ companies spanning six continents, 20 countries and 70+ cities), StartUp Health is mobilizing this rapidly growing army along with the world’s ‘batteries included’ leaders, innovators, and investors to achieve 10 Health Moonshots, with a 25-year mission to improve the health and wellbeing of everyone in the world.
GBCHealth is a coalition of companies and organizations committed to investing their resources to make a healthier world… for their employees, for the communities in which they work and for the world at large.
Since 2001 GBCHealth has helped hundreds of companies develop and implement their own global health programs, brokered countless global and local public-private partnerships and connections and effectively leveraged business advocacy in service of public health. Through convening’s, partnership creation, advocacy and thought leadership, innovative financing and spearheading carefully selected initiatives, GBCHealth is the advisor of choice for companies interested in bringing their assets, skills and passion to help meet our shared goals for health.
Media Partner (1)
Empowered Doctor was one of the original, online medical marketing and news organizations - at the forefront of the healthcare publishing and advertising revolution. Its work developing quality online medical news helped shape how Internet search functions today. In addition, it is the media partner for Castle Connolly’s “National Physician of the Year Awards.” Since 2006, The National Physician of the Year Awards has recognized the physicians and leaders in health care, whose dedication, talents, and skills have improved the lives of millions of people throughout the world.
- Sharp rise in patients suffering from several long-term diseases
- The doctor will see you now — on your smartphone
- Financial burden of dementia is set to grow
- Saline investigation highlights the cost of American healthcare
- Billionaires battle to fix the US healthcare system
- Amazon, Berkshire and JPMorgan join forces to shake up healthcare
- To improve global health, tax the things that are killing us